CTMX Q3 2025 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-82.2% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$16M-264.4% margin

Net Income

-$14M-238.6% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-68.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$158M

Total Liabilities

$51M

Stockholders' Equity

$107M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$33M	-82.2%
Gross Profit	$6M	$33M	-82.2%
Operating Income	-$16M	$4M	-483.6%
Net Income	-$14M	$6M	-348.1%